The next generation of blockbuster obesity drugs isn’t trying to replace GLP-1 medicines. Instead, drugmakers are developing treatments that can complement existing drugs and push weight loss furthe… [+7091 chars]Read More
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP1s CNBC
